321 related articles for article (PubMed ID: 28782830)
1. Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease.
Hsu YT; Chang YG; Chang CP; Siew JJ; Chen HM; Tsai CH; Chern Y
Mov Disord; 2017 Nov; 32(11):1600-1609. PubMed ID: 28782830
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Na
Hsu YT; Chang YG; Liu YC; Wang KY; Chen HM; Lee DJ; Yang SS; Tsai CH; Lien CC; Chern Y
Mov Disord; 2019 Jun; 34(6):845-857. PubMed ID: 30840784
[TBL] [Abstract][Full Text] [Related]
3. Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3.
Wójtowicz AM; Dvorzhak A; Semtner M; Grantyn R
Front Neural Circuits; 2013; 7():188. PubMed ID: 24324407
[TBL] [Abstract][Full Text] [Related]
4. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
5. Enhanced behavioral sensitivity to the competitive GABA agonist, gaboxadol, in transgenic mice over-expressing hippocampal extrasynaptic alpha6beta GABA(A) receptors.
Saarelainen KS; Ranna M; Rabe H; Sinkkonen ST; Möykkynen T; Uusi-Oukari M; Linden AM; Lüddens H; Korpi ER
J Neurochem; 2008 Apr; 105(2):338-50. PubMed ID: 18021290
[TBL] [Abstract][Full Text] [Related]
6. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
[TBL] [Abstract][Full Text] [Related]
7. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
8. Enhanced striatopallidal gamma-aminobutyric acid (GABA)
Perez-Rosello T; Gelman S; Tombaugh G; Cachope R; Beaumont V; Surmeier DJ
Mov Disord; 2019 May; 34(5):684-696. PubMed ID: 30726572
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.
Denovan-Wright EM; Robertson HA
Neuroscience; 2000; 98(4):705-13. PubMed ID: 10891614
[TBL] [Abstract][Full Text] [Related]
10. Comparing the discriminative stimulus effects of modulators of GABAA receptors containing α4-δ subunits with those of gaboxadol in rats.
Zanettini C; Pressly JD; Ibarra MH; Smith KR; Gerak LR
Psychopharmacology (Berl); 2016 May; 233(10):2005-13. PubMed ID: 26900079
[TBL] [Abstract][Full Text] [Related]
11. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
12. Deletion of the fyn-kinase gene alters sensitivity to GABAergic drugs: dependence on beta2/beta3 GABAA receptor subunits.
Boehm SL; Peden L; Harris RA; Blednov YA
J Pharmacol Exp Ther; 2004 Jun; 309(3):1154-9. PubMed ID: 14764659
[TBL] [Abstract][Full Text] [Related]
13. Regional and subcellular distribution of GABA
Kumar U; Heer M; Somvanshi RK
Neurosci Lett; 2017 Feb; 640():81-87. PubMed ID: 28104430
[TBL] [Abstract][Full Text] [Related]
14. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
Ferrante A; Martire A; Armida M; Chiodi V; Pézzola A; Potenza RL; Domenici MR; Popoli P
Brain Res; 2010 Apr; 1323():184-91. PubMed ID: 20138162
[TBL] [Abstract][Full Text] [Related]
15. Effects of Diazepam on Low-Frequency and High-Frequency Electrocortical γ-Power Mediated by α1- and α2-GABA
Hofmann JI; Schwarz C; Rudolph U; Antkowiak B
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31315211
[TBL] [Abstract][Full Text] [Related]
16. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
17. delta-Subunit containing GABAA receptor knockout mice are less sensitive to the actions of 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol.
Boehm SL; Homanics GE; Blednov YA; Harris RA
Eur J Pharmacol; 2006 Jul; 541(3):158-62. PubMed ID: 16777089
[TBL] [Abstract][Full Text] [Related]
18. Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence.
Liang J; Cagetti E; Olsen RW; Spigelman I
J Pharmacol Exp Ther; 2004 Sep; 310(3):1234-45. PubMed ID: 15126642
[TBL] [Abstract][Full Text] [Related]
19. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.
Dowie MJ; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2010 Sep; 170(1):324-36. PubMed ID: 20600638
[TBL] [Abstract][Full Text] [Related]
20. Deletion of the alpha1 or beta2 subunit of GABAA receptors reduces actions of alcohol and other drugs.
Blednov YA; Jung S; Alva H; Wallace D; Rosahl T; Whiting PJ; Harris RA
J Pharmacol Exp Ther; 2003 Jan; 304(1):30-6. PubMed ID: 12490572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
